We evaluated the activity and toxic effects of bortezomib in patients with mantle cell lymphoma.
PATIENTS AND METHODS
Thirty patients, including 29 eligible patients, were enrolled; 13 had received no prior chemotherapy. The dose of bortezomib was 1.3 mg/m2 given on days 1, 4, 8 and 11 every 21 days. Response was assessed according to the… (More)